Male Sexual Dysfunction - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 151

Male Sexual Dysfunction – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Male Sexual Dysfunction - Pipeline Review, H1 2012', provides an overview of the Male Sexual Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. 'Male Sexual Dysfunction - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Male Sexual Dysfunction.
- A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Male Sexual Dysfunction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Male Sexual Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Male Sexual Dysfunction pipeline depth and focus of Male Sexual Dysfunction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Male Sexual Dysfunction Therapeutic Products under Development, Key Players in Male Sexual Dysfunction Therapeutics, Male Sexual Dysfunction Pipeline Overview, Male Sexual Dysfunction Pipeline, Male Sexual Dysfunction Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Sexual Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Male Sexual Dysfunction
Male Sexual Dysfunction Therapeutics under Development by Companies
Male Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Male Sexual Dysfunction Therapeutics – Products under Development by Companies
Male Sexual Dysfunction Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Male Sexual Dysfunction Therapeutics Development
Johnson & Johnson
Shionogi & Co., Ltd.
Eli Lilly and Company
GlaxoSmithKline plc
Vectura Group plc
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
VIVUS, Inc.
Warner Chilcott Limited
Bayer AG
IntelGenx Technologies Corp.
NexMed, Inc.
NovaDel Pharma, Inc.
Palatin Technologies, Inc.
Yuhan Corporation
Repros Therapeutics Inc.
Futura Medical plc.
Plethora Solutions Holdings plc
Rexahn Pharmaceuticals, Inc.
Global Health Ventures Inc.
Cordex Pharma, Inc.
Quatrx Pharmaceutical Company
Medisyn Technologies, Inc.
NeuroHealing Pharmaceuticals Inc.
Ampio Pharmaceuticals, Inc.
Male Sexual Dysfunction – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Avanafil - Drug Profile
PSD502 - Drug Profile
PL-6983 - Drug Profile
Vitaros - Drug Profile
Bremelanotide - Drug Profile
X-Excite - Drug Profile
Zoraxel - Drug Profile
Androxal - Drug Profile
VR004 - Drug Profile
VR776 - Drug Profile
Duromist - Drug Profile
Invicorp - Drug Profile
CKD 533 - Drug Profile
NH02D - Drug Profile
Viagra - Drug Profile
Alfuzosin - Drug Profile
Radiation Therapy + Leuprolide Acetate - Drug Profile
Pilocarpine Hydrochloride - Drug Profile
Anastrozole - Drug Profile
Bone Marrow Mononucleated Cells - Drug Profile
Testosterone - Drug Profile
Zydena - Drug Profile
DA-8031 - Drug Profile
GSK557296 - Drug Profile
Viagra - Drug Profile
BAY60-4552 + Vardenafil - Drug Profile
Testim + Viagra - Drug Profile
LY900010 - Drug Profile
Fispemifene - Drug Profile
Escitalopram - Drug Profile
Priligy - Drug Profile
Avanafil - Drug Profile
INT 0007 - Drug Profile
Dehydroepiandrosterone - Drug Profile
Testosterone Gel - Drug Profile
Testosterone - Drug Profile
Folic Acid + Tadalafil - Drug Profile
Simvastatin - Drug Profile
WC3036 - Drug Profile
PET500 - Drug Profile
Avanafil + Enalapril - Drug Profile
Avanafil + Amlodipine - Drug Profile
Clomipramine - Drug Profile
PDE5 Inhibition - Drug Profile
MC4R Agonist - Drug Profile
Drug For Premature Ejaculation - Drug Profile
NanoActive Sildenafil Citrate - Drug Profile
Zertane - Drug Profile
YHD1023 - Drug Profile
SPI-1972 - Drug Profile
TUC204 - Drug Profile
Male Sexual Dysfunction Therapeutics – Drug Profile Updates
Male Sexual Dysfunction Therapeutics – Discontinued Products
Male Sexual Dysfunction Therapeutics - Dormant Products
Male Sexual Dysfunction – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Male Sexual Dysfunction, H1 2012
Products under Development for Male Sexual Dysfunction – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Johnson & Johnson, H1 2012
Shionogi & Co., Ltd., H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Vectura Group plc, H1 2012
Chong Kun Dang Pharmaceutical, H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
VIVUS, Inc., H1 2012
Warner Chilcott Limited, H1 2012
Bayer AG, H1 2012
IntelGenx Technologies Corp., H1 2012
NexMed, Inc., H1 2012
NovaDel Pharma, Inc., H1 2012
Palatin Technologies, Inc., H1 2012
Yuhan Corporation, H1 2012
Repros Therapeutics Inc., H1 2012
Futura Medical plc., H1 2012
Plethora Solutions Holdings plc, H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
Global Health Ventures Inc., H1 2012
Cordex Pharma, Inc., H1 2012
Quatrx Pharmaceutical Company, H1 2012
Medisyn Technologies, Inc., H1 2012
NeuroHealing Pharmaceuticals Inc., H1 2012
Ampio Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Male Sexual Dysfunction Therapeutics – Drug Profile Updates
Male Sexual Dysfunction Therapeutics – Discontinued Products
Male Sexual Dysfunction Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Male Sexual Dysfunction, H1 2012
Products under Development for Male Sexual Dysfunction – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Erectile Dysfunction – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013